Recruitment Progress

Descriptive statistics for GALA I and GALA II study participants

  GALA I GALA II SAGE II

Descriptive Statistics

Mexican

Puerto Rican

Latino case

Latino control

African American case

African American control

N 294 365 2232 2228 908 616
N with mRNA 0 0 1305 1022 372 327
Age, yr, median (25:75th quartiles) 13.2 (11:20) 11.9
(10:15)
12.2
(10:15)
13.4
(11:17)
13.7
(11:17)
15.9
(12:19)
Sex, % male 53.8 55.6 54.5 43.7 51.3 44.3
BMI, kg/m2, median (25:75th quartiles) 23.7 (20:28) 21.2
(17:26)
22.3
(19:27)
23.6
(20:28)
23.2
(20:28)
22.9
(20:27)
Asthma Duration, yr, median (25:75th) 7
(3:10)
9
(7:12)
9.2
(6:12)
NA
(NA:NA)
9.8
(7:13)
NA
(NA:NA)
Atopic eczema or allergic rhinitis, % 81.4 84.9 79.9 30.9 84.8 27.4

Pulmonary Function

Baseline FEV1 (% of predicted) 90
(77:100)
83
(74:93)
91.4
(82:101)
98.4
(91:108)
82.3
(75:91)
86.5
(80:94)
Baseline FVC (% of predicted) 97
(86:109)
94
(83:105)
94.8
(85:105)
97.9
(90:108)
87.3
(80:95)
87.1
(81:94)
Baseline FEV1/FVC (% of predicted) 92
(87:99)
90
(82:97)
96.8
(91:102)
101.6
(96:106)
95.7
(89:101)
99.5
(95:105)
Max response to albuterol (% change) 7.4 (4:12) 4.8 (0.5:10) 7.4(4:12)   6.5(4:11)